Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.

Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
复制标题

DOI:
10.1073/pnas.2205085120
复制
发表时间:
2023-04-18
影响因子:
11.1
通讯作者:
--
中科院分区:
综合性期刊1区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

程序性死亡配体1(PD-L1)与CD80的相互作用可以是顺式或反式的,但在体内PD-L1如何与CD80相互作用仍存在争议。特异性阻断抗原呈递细胞(APCs)上顺式PD-L1/CD80的相互作用会降低肿瘤免疫,但全面阻断PD-L1/CD80相互作用对肿瘤免疫的影响尚不清楚。我们的研究表明,在体内,T细胞与肿瘤细胞之间确实存在反式PD-L1/CD80相互作用,并且在体内阻断反式PD-L1/CD80相互作用或全面阻断PD-L1/CD80相互作用,可通过在肿瘤组织中扩增产生γ干扰素(IFN-γ)的CD8 + T细胞和诱导型一氧化氮合酶2(NOS2)阳性巨噬细胞来增强肿瘤免疫。这些结果表明,在体内,肿瘤细胞与T细胞之间的反式PD-L1/CD80相互作用比顺式PD-L1/CD80相互作用占优势。 PD-L1有两个受体:程序性死亡受体1(PD-1)和CD80。先前的报道认为PD-L1与CD80以反式相互作用,但最近的报道显示仅存在顺式PD-L1/CD80相互作用,并且阻断APCs上顺式PD-L1/CD80相互作用会通过增强T细胞与APCs之间的PD-L1/PD-1和CD80/细胞毒性T淋巴细胞相关蛋白4(CTLA4)相互作用来降低抗肿瘤免疫。在此,我们利用能够产生顺式和反式或仅反式PD-L1/CD80相互作用的荷瘤小鼠,证明了肿瘤细胞与T细胞之间确实存在反式PD-L1/CD80相互作用,且反式PD-L1/CD80相互作用的效应需要肿瘤细胞表达主要组织相容性复合体I类分子(MHC-I)以及T细胞表达CD28。在同时存在顺式和反式相互作用或仅存在反式相互作用的小鼠中,阻断PD-L1/CD80相互作用,可通过扩增产生IFN-γ的CD8 + T细胞和依赖IFN-γ表达NOS2的肿瘤相关巨噬细胞来增强抗肿瘤免疫。我们的研究表明,尽管顺式和反式PD-L1/CD80相互作用可能对抗肿瘤免疫产生相反的影响,但在体内阻断PD-L1/CD80相互作用的总体效应是增强CD8 + T细胞介导的抗肿瘤免疫。
PD-L1 interaction with CD80 can be in cis or in trans, but how PD-L1 interacts with CD80 in vivo remains controversial. Specific blockade of cis PD-L1/CD80 interactions on APCs reduces tumor immunity, but the impact of general blockade of PD-L1/CD80 interactions on tumor immunity remains unclear. Our studies demonstrate that in vivo trans PD-L1/CD80 interactions do exist between T and tumor cells, and in vivo blockade of trans PD-L1/CD80 interactions or general PD-L1/CD80 interactions augment tumor immunity via expansion of IFN-γ-producing CD8+T cells and NOS2+macrophages in the tumor tissues. These results indicate that in vivo trans PD-L1/CD80 interactions between tumor and T cells are dominant over cis PD-L1/CD80 interactions. PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 and CD80/CTLA4 interactions between T and APCs. Here, using tumor-bearing mice capable of cis and trans or trans only PD-L1/CD80 interactions, we show that trans PD-L1/CD80 interactions do exist between tumor and T cells, and the effects of trans PD-L1/CD80 interactions require tumor cell expression of MHC-I and T cell expression of CD28. The blockade of PD-L1/CD80 interactions in mice with both cis and trans interactions or with only trans interactions augments antitumor immunity by expanding IFN-γ–producing CD8+ T cells and IFN-γ–dependent NOS2-expressing tumor-associated macrophages. Our studies indicate that although cis and trans PD-L1/CD80 interactions may have opposite effects on antitumor immunity, the net effect of blocking PD-L1/CD80 interactions in vivo augments CD8+ T cell-mediated antitumor immunity.
B7H1/CD80 相互作用增强 PD-1 依赖性 T 细胞凋亡并改善移植物抗宿主病
DOI: 10.4049/jimmunol.1402157
发表时间: 2015-01-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Deng R;Cassady K;Li X;Yao S;Zhang M;Racine J;Lin J;Chen L;Zeng D
通讯作者: Zeng D
DOI: 10.1016/j.immuni.2007.05.016
发表时间: 2007-07-01
期刊: IMMUNITY
影响因子: 32.4
作者:
Butte, Manish J.;Keir, Mary E.;Freeman, Gordon J.
通讯作者: Freeman, Gordon J.
DOI: 10.1038/mt.2016.121
发表时间: 2016-08-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Erkes, Dan A.;Xu, Guangwu;Snyder, Christopher M.
通讯作者: Snyder, Christopher M.
DOI: 10.1158/2326-6066.cir-17-0316
发表时间: 2018-08
影响因子: 10.1
作者:
Chaudhri A;Xiao Y;Klee AN;Wang X;Zhu B;Freeman GJ
通讯作者: Freeman GJ
DOI: 10.1084/jem.177.3.845
发表时间: 1993-03-01
影响因子: 15.3
作者:
Azuma, M;Yssel, H;Phillips, J H;Spits, H;Lanier, L L
通讯作者: Lanier, L L